Variations in predicted regional lung deposition of salbutamol sulphate between 19 nebulizer types

被引:22
作者
Finlay, WH [1 ]
Stapleton, KW [1 ]
Zuberbuhler, P [1 ]
机构
[1] Univ Alberta, Dept Mech Engn, Edmonton, AB T6G 2G8, Canada
来源
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG | 1998年 / 11卷 / 02期
关键词
aerosol; nebulize; bronchodilator; albuterol;
D O I
10.1089/jam.1998.11.65
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Regional lung dosages are estimated for 19 different nebulizer types, and variations in these dosages within each nebulizer type are given. Experimental methods are used to characterize the aerosols inhaled in vitro (inhalation flow rate = 300 mL/s, tidal volume = 750 mL) from nebulizers filled with 2.5 mL of Ventolin (1 mg/mL of salbutamol sulphate in normal saline) under ambient conditions of 50% +/- 3% relative humidity (RH), 22 degrees C +/- 1 degrees C. These data are input into a hygroscopic, mathematical lung deposition model to estimate regional lung dosages for a scaled Weibel A lung. The deposition model is a two-way coupled model (i.e., it includes the effects of droplet heat and mass transfer on the surrounding environment and vice versa). As a percentage of normal dose placed in the nebulizer, regional dosages differed significantly between the different nebulizer types (P < 0.01) and varied from 3.1% to 23.4%, 1.6% to 10.6%, 1.6% to 12.8%, and 1.8% to 9.5% for lung, tracheobronchial, alveolar, and extrathoracic deposition, respectively. Variations in regional dosages between nebulizers of each type had standard deviations that mere, on average, less than 2% of the nominal dose. Of the three nebulizer classes tested (ultrasonic, conventional, and vented), no class consistently gave higher regional dosages than the other two classes. Good agreement with published in vivo scintigraphic data mas found (P > 0.01) in lung dosages.
引用
收藏
页码:65 / 80
页数:16
相关论文
共 36 条
[1]  
[Anonymous], 1966, HEALTH PHYS, V12, P173
[2]  
[Anonymous], J AEROSOL SCI
[3]  
[Anonymous], AEROSOLS MED PRINCIP
[4]  
BENNETT WD, 1988, J AEROSOL MED, V1, P67
[5]   CHARACTERIZATION OF AEROSOLS OF HUMAN RECOMBINANT DEOXYRIBONUCLEASE-I (RHDNASE) GENERATED BY JET NEBULIZERS [J].
CIPOLLA, D ;
GONDA, I ;
SHIRE, SJ .
PHARMACEUTICAL RESEARCH, 1994, 11 (04) :491-498
[6]  
CIPOLLA DC, 1994, STP PHARMA SCI, V4, P50
[7]   THE USE OF LASER DIFFRACTION FOR THE EVALUATION OF THE AEROSOL CLOUDS GENERATED BY MEDICAL NEBULIZERS [J].
CLARK, AR .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 115 (01) :69-78
[8]   MODELING THE DEPOSITION OF INHALED POWDERED DRUG AEROSOLS [J].
CLARK, AR ;
EGAN, M .
JOURNAL OF AEROSOL SCIENCE, 1994, 25 (01) :175-186
[9]   DRUG NEBULIZER DESIGN AND PERFORMANCE - BREATH ENHANCED JET VS CONSTANT OUTPUT JET VS ULTRASONIC [J].
DENNIS, JH .
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 1995, 8 (03) :277-280
[10]  
Devore J., PROBABILITY STAT ENG